Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Bttinger L, Klay D, et al
Kim S, No YH, Sluyter R, Konstantinov K, Kim YH, Kim JH
Peptides: Tesamorelin, AOD9604, Tirzepatide (GLP-1 agonist) Tesamorelin is FDA-approved to reduce visceral adipose tissue (VAT) in HIV-associated lipodystrophy, but its fat-burning effects also appear in non-HIV populations AOD9604 is a modified fragment of human GH (176191) shown in animal and early human trials to enhance lipolysis without altering blood sugar or cortisol Tirzepatide , while technically a GLP-1/GIP agonist , is now frequently stacked with peptides in clinical practice to accelerate fat loss and appetite control
The timing of administration varies in the research literature